Patient demographics, selected laboratory values, clinical history, and immunotherapy drugs included in this study
| Age | |
| Median | 53.5 |
| Range | 18–84 |
| Sex | |
| Female | 29 |
| Male | 21 |
| No. of metastatic sites | |
| < 3 | 37 |
| > =3 | 13 |
| LDH | |
| < =ULN | 36 |
| > ULN | 14 |
| ECOG PS | |
| 0–1 | 48 |
| 2 | 2 |
| Albumin | |
| > =3.5 g/dl | 46 |
| < 3.5 g/dl | 4 |
| RMH score | |
| < 2 | 43 |
| > =2 | 7 |
| Prior treatments | |
| Median | 3 |
| Range | 0–12 |
| Anthracycline | 30 |
| Ifosfamide | 14 |
| Gemcitabine | 22 |
| Docetaxel | 13 |
| Platinum | 8 |
| Investigational therapies | |
| anti-CCR4 and anti-PD-L1 | 4 |
| anti-PD-1 | 7 |
| anti-PD-L1 | 7 |
| anti-TIM-3 | 1 |
| anti-CTLA-4 | 5 |
| anti-CTLA-4 and immunomodulator | 7 |
| anti-CTLA-4 and KIT inhibitor | 10 |
| Dendritic cell vaccine | 7 |
| Interleukin-2 | 1 |
| anti-TGF-β | 1 |